Comparison of clinical outcomes between FA and placebo groups
| . | FA (n = 28) . | Placebo (n = 24) . | P . |
|---|---|---|---|
| Grades 3 or 4 oral mucositis, % | 46.6 | 45.8 | .97 |
| Duration of grade 3 or 4 oral mucositis, median d (range) | 4 (2-10) | 4 (3-6) | .43 |
| Grades 1 to 4 oral mucositis, % | 83.3 | 77.8 | .65 |
| Day of neutrophil engraftment, median (range) | 12 (10-21) | 12 (11-18) | .58 |
| Day of platelets engraftment, median (range) | 13 (0-37) | 13 (14-24) | .4 |
| Febrile neutropenia, % | 57.1 | 58.3 | .94 |
| Blood stream infection, % | 10.7 | 16.6 | .53 |
| SOS, % | 7 | 12.5 | .5 |
| TPN, % | 14.2 | 25 | .32 |
| Use of IV opiates, % | 78.5 | 66.6 | .34 |
| Days from HCT to discharge, median (range) | 18.5 (12-69) | 19 (12-39) | .95 |
| . | FA (n = 28) . | Placebo (n = 24) . | P . |
|---|---|---|---|
| Grades 3 or 4 oral mucositis, % | 46.6 | 45.8 | .97 |
| Duration of grade 3 or 4 oral mucositis, median d (range) | 4 (2-10) | 4 (3-6) | .43 |
| Grades 1 to 4 oral mucositis, % | 83.3 | 77.8 | .65 |
| Day of neutrophil engraftment, median (range) | 12 (10-21) | 12 (11-18) | .58 |
| Day of platelets engraftment, median (range) | 13 (0-37) | 13 (14-24) | .4 |
| Febrile neutropenia, % | 57.1 | 58.3 | .94 |
| Blood stream infection, % | 10.7 | 16.6 | .53 |
| SOS, % | 7 | 12.5 | .5 |
| TPN, % | 14.2 | 25 | .32 |
| Use of IV opiates, % | 78.5 | 66.6 | .34 |
| Days from HCT to discharge, median (range) | 18.5 (12-69) | 19 (12-39) | .95 |